• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by AlloVir Inc.

    2/14/25 1:17:23 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Allovir, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    019818202

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    019818202


    1Names of Reporting Persons

    EcoR1 Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    408,688.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    408,688.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    408,688.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.1 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on 5,041,932 shares of Common Stock outstanding on January 30, 2025, following the 1-for-23 reverse split of the Issuer's Common Stock, as reported in the Proxy Statement filed by the Issuer February 10, 2025.


    SCHEDULE 13G

    CUSIP No.
    019818202


    1Names of Reporting Persons

    Oleg Nodelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    408,688.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    408,688.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    408,688.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.1 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on 5,041,932 shares of Common Stock outstanding on January 30, 2025, following the 1-for-23 reverse split of the Issuer's Common Stock, as reported in the Proxy Statement filed by the Issuer February 10, 2025.


    SCHEDULE 13G

    CUSIP No.
    019818202


    1Names of Reporting Persons

    EcoR1 Capital Fund Qualified, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    385,705.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    385,705.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    385,705.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on 5,041,932 shares of Common Stock outstanding on January 30, 2025, following the 1-for-23 reverse split of the Issuer's Common Stock, as reported in the Proxy Statement filed by the Issuer February 10, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Allovir, Inc.
    (b)Address of issuer's principal executive offices:

    P.O. Box 44, 1661 Massachusetts Avenue, Lexington, MA 02420
    Item 2. 
    (a)Name of person filing:

    EcoR1 Capital, LLC, a Delaware limited liability company ("EcoR1") EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership ("Qualified Fund") Oleg Nodelman Qualified Fund is filing this statement jointly with the other reporting persons, but not as a member of a group, and it expressly disclaims membership in a group. In addition, the filing of this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any securities covered by this Schedule 13G. Each reporting person also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    357 Tehama Street #3, San Francisco, CA 94103
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    019818202
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    EcoR1: 408,688 Qualified Fund: 385,705 Oleg Nodelman: 408,688
    (b)Percent of class:

    EcoR1: 8.1% Qualified Fund: 7.7% Oleg Nodelman: 8.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    EcoR1: 0 Qualified Fund: 0 Oleg Nodelman: 0

     (ii) Shared power to vote or to direct the vote:

    EcoR1: 408,688 Qualified Fund: 385,705 Oleg Nodelman: 408,688

     (iii) Sole power to dispose or to direct the disposition of:

    EcoR1: 0 Qualified Fund: 0 Oleg Nodelman: 0

     (iv) Shared power to dispose or to direct the disposition of:

    EcoR1: 408,688 Qualified Fund: 385,705 Oleg Nodelman: 408,688

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    EcoR1 Capital, LLC
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager
    Date:02/14/2025
     
    Oleg Nodelman
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Reporting person
    Date:02/14/2025
     
    EcoR1 Capital Fund Qualified, L.P.
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
    Date:02/14/2025
    Get the next $ALVR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALVR

    DatePrice TargetRatingAnalyst
    12/26/2023$17.00 → $1.00Buy → Underperform
    BofA Securities
    12/22/2023Outperform → Market Perform
    Leerink Partners
    12/22/2023Overweight → Underweight
    JP Morgan
    12/22/2023Overweight → Neutral
    Piper Sandler
    8/18/2023$17.00Buy
    BofA Securities
    2/10/2022$32.00 → $30.00Outperform
    SVB Leerink
    1/18/2022$48.00 → $45.00Overweight
    Morgan Stanley
    12/17/2021$37.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $ALVR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      3/4/24 5:37:52 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

      2/28/24 1:06:25 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

      Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (NASDAQ:ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-s

      12/22/23 7:00:00 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by AlloVir Inc.

      SC 13G - Allovir, Inc. (0001754068) (Subject)

      10/11/24 4:02:13 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AlloVir Inc.

      SC 13G/A - Allovir, Inc. (0001754068) (Subject)

      8/2/24 6:25:25 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by AlloVir Inc. (Amendment)

      SC 13G/A - Allovir, Inc. (0001754068) (Subject)

      2/13/24 4:54:00 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by AlloVir Inc.

      SCHEDULE 13D - Kalaris Therapeutics, Inc. (0001754068) (Subject)

      3/25/25 7:40:09 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by AlloVir Inc.

      SCHEDULE 13G/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)

      3/20/25 4:32:25 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Leadership Update, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Regulation FD Disclosure

      8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)

      3/18/25 5:04:06 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AlloVir downgraded by BofA Securities with a new price target

      BofA Securities downgraded AlloVir from Buy to Underperform and set a new price target of $1.00 from $17.00 previously

      12/26/23 7:17:53 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir downgraded by Leerink Partners

      Leerink Partners downgraded AlloVir from Outperform to Market Perform

      12/22/23 10:47:30 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir downgraded by JP Morgan

      JP Morgan downgraded AlloVir from Overweight to Underweight

      12/22/23 9:11:15 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Leadership Updates

    Live Leadership Updates

    See more
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      3/4/24 5:37:52 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

      2/28/24 1:06:25 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer

      - Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company's commercial strategy and capabilities - AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Cintia Piccina, PharmD, MBA, as the company's Chief Commercial Officer, effective June 12, 2023. Ms. Piccina will drive the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and be responsible for building a commercial team in anticipation of a 2025 launch. "Cintia is an accomplished executive with a track record of successful cell therapy and oncology

      5/16/23 7:00:00 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Hagen Brett R sold $8,135 worth of shares (907 units at $8.97), decreasing direct ownership by 32% to 1,925 units (SEC Form 4)

      4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

      3/27/25 7:19:58 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: New insider Akkaraju Srinivas claimed ownership of 3,578 shares (SEC Form 3)

      3/A - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

      3/26/25 5:06:57 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Samsara Biocapital Gp, Llc claimed ownership of 11,448,081 shares (SEC Form 3)

      3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

      3/25/25 7:38:53 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care